ClinicalTrials.gg
Active, not recruitingNCT04826705PROMISINGUpdated Mar 5, 2024

A Study of Endovascular Treatment of Femoropopliteal Arterial Occlusive Lesion With Drug-Coated Balloon

An observational study in Drug-coated Balloon, Femoropopliteal Artery Occlusion and Angioplasty, sponsored by Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology. Active, not recruiting at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

There have been a number of randomized controlled studies (RCT) showing the efficacy of the endovascular treatment with drug-coated balloons (DCB) in the femoropopliteal artery lesions. However, these studies have been carefully designed, and most of them have excluded long-length lesions and severely calcified lesions. In addition to being used alone in the real word, drug-coated balloons (DCB) are also used in combination with stents or debulking devices, but in these randomized controlled studies (RCT) they are only compared with standard percutaneous transluminal angioplasty (PTA). Therefore, the investigators initiated this study, which is a prospective, multicenter, observational real-world study of short and long-term outcome in endovascular treatment of femoropopliteal arterial occlusive lesions with DCB.

Read the detailed description

Traditional endovascular approaches to the treatment of atherosclerotic disease in the femoropopliteal arteries include percutaneous transluminal angioplasty (PTA) with an uncoated balloon and implantation of a bare metal stent. Recently, drug-eluting stents (DES) and drug-coated balloons (DCB) that transfer paclitaxel to the vessel wall during revascularization have been added to the suite of tools available to interventionists, helping to prevent restenosis after treatment.

There have been a number of randomized controlled studies (RCT) showing the efficacy of the endovascular treatment with drug-coated balloons (DCB) in the femoropopliteal artery lesions. However, these studies have been carefully designed, and most of them have excluded long-length lesions and severely calcified lesions. In addition to being used alone in the real word, drug-coated balloons (DCB) are also used in combination with stents or debulking devices, but in these randomized controlled studies (RCT) they are only compared with standard percutaneous transluminal angioplasty (PTA).

Therefore, the investigators initiated this study, which is a prospective, multicenter, observational real-world study of short and long-term outcome in endovascular treatment of femoropopliteal arterial occlusive lesions with DCB. It is estimated that 1200 patients with chronic femoral popliteal artery occlusion were enrolled in the group at 8 centers in China in two years. The follow-up would be conducted at 1, 3, 6, 12, 18, 24, 36 and 48 months after the operation to assess the efficacy and safety of the endovascular treatment with drug-coated balloons (DCB) in the femoropopliteal artery lesions.

02

Conditions studied

  • Drug-coated Balloon
  • Femoropopliteal Artery Occlusion
  • Angioplasty
03

In context

Lead sponsor

Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with femoralpopliteal artery occlusion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Rutherford grade 2-5.
  2. Femoral popliteal artery stenosis or occlusion, a clear outflow tract no less than 10cm long at the distal end of the knee should be continuous with a clear outflow tract under the ankle.
  3. Patients who understand the purpose of this study, volunteer to participate in the experiment, sign and are willing to follow up.
  4. The guide wire needs to pass through the lesion.
  5. > 24 months.
  6. Patients with thrombosis of the lower extremities, patients who received drug-coated balloon (DCB) intervention after thrombus removal through mechanical thrombus removal, percutaneous catheter thrombolysis, and thrombus removal.
  7. Patients who have received DCB intervention for both lower limbs can be enrolled in the group according to the intracavitary treatment time.
  8. There is at least one continuous infrapopliteal outflow artery or obtained through intravascular reconstruction.
  9. For combined aortic iliac artery disease, the blood flow can be recanalized after intravascular reconstruction without residual stenosis exceeding 50%.

Exclusion criteria

Exclusion Criteria:

  1. Patients with stroke, cerebral hemorrhage, gastrointestinal hemorrhage or myocardial infarction within 3 months before enrollment.
  2. Patients who are known to be allergic to heparin, aspirin, other antiplatelet drugs, contrast agents, etc.
  3. Patients who have participated in clinical trials of drugs or other medical devices that interfere with this clinical trial within the past 3 months.
  4. Pregnant and lactating women.
  5. Patients who are unable or unwilling to participate in this trial.
  6. Patients with Berg's disease.
  7. Patients who have undergone arterial bypass on the treatment side.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (actual)
Target follow-up
4 Years
Patient registry
Yes

Interventions

  • DeviceDrug-coated Balloon

    To observe the effectiveness and safety of the drug-coated balloon in the treatment of lower extremity arteriosclerosis obliterans of the femoral popliteal artery segment.

06

What researchers measure

Primary outcomes

  1. Freedom from clinically-driven target lesion revascularization(CD-TLR) rate at post-interventional

    Clinically-driven target lesion revascularization (CD-TLR) is defined as any re-intervention within the target lesion due to symptoms or drop of ankle brachial index (ABI) of ≥20% or \>0.15 when compared to post-procedure baseline.

    Time frame: 48 months

  2. Major adverse events

    Operation-related acute thrombosis, arterial embolism, major amputation and all-cause mortality.

    Time frame: 48 months

Secondary outcomes

  1. Changes of the patency rate of target lesions at post-interventional

    The patency rate of target(Femoropopliteal) lesions would be determined by vascular ultrasound,Restenosis would be diagnosed if the peak systolic velocity ratio(PSVR)≥2. 5.

    Time frame: 1 month, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months

  2. Technical success rate

    Successfully revascularize the target vessel. The residual stenosis is \<30% and there is no acute thrombosis occurred in the target vessel within 1 week post-operation.

    Time frame: 1 week

  3. Vascular quality of life questionnaire(VascuQol)

    The VascuQol was designed as a questionnaire containing five domains: pain (4 items), symptoms (4 items), activities (8 items), social (2 items), and emotional (7 items) to evaluate Health related quality of life (HRQL). Every item has seven response options, with scores ranging from 1 to 7. A total score is the sum of all 25 item scores divided by 25.And both the total score as well as the domain scores range from 1 (worst HRQL) to 7 (best HRQL).The lower the value, the poorer the quality of life.

    Time frame: 1 month, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months

  4. The patient's ulcer healing

    Ulcer healing in patients with Rutherford grade 5

    Time frame: 1 month, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months

  5. Freedom from clinically-driven target lesion revascularization(CD-TLR) rate at post-interventional

    Clinically-driven target lesion revascularization (CD-TLR) is defined as any re-intervention within the target lesion due to symptoms or drop of ankle brachial index (ABI) of ≥20% or \>0.15 when compared to post-procedure baseline.

    Time frame: 1 month, 3 months, 6 months, 12 months, 24 months, 36 months

  6. Major adverse events

    Operation-related acute thrombosis, arterial embolism, major amputation and all-cause mortality.

    Time frame: 1 month, 3 months, 6 months, 12 months, 24 months, 36 months

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: Undecided — Share data with multi-center participants in this study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2021 (actual). Primary completion is estimated for Feb 2025, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2021
First posted
Apr 1, 2021
StartActual
Feb 1, 2021
Primary completionEst.
Feb 1, 2025
CompletionEst.
Feb 1, 2027
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04826705
Lead sponsor
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Collaborators
RenJi Hospital, Zhejiang University, Xuanwu Hospital, Beijing, First People's Hospital of Hangzhou, Second Affiliated Hospital of Suzhou University, Qingdao University, Chengdu University of Traditional Chinese Medicine
Responsible party
Zibo Feng (Director of Vascular Surgery, Liyuan Hospital, Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Apr 1, 2021
Start date
Feb 1, 2021
Primary completion
Feb 1, 2025 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Mar 5, 2024

Study contacts

Zibo Feng
principal investigator · Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology

Start the discussion